Literature DB >> 2202336

Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris.

L Kemény1, T Ruzicka, O Braun-Falco.   

Abstract

Dithranol is highly effective in the treatment of psoriasis. The drug inhibits keratinocyte hyperproliferation, granulocyte function and, in addition, may exert an immunosuppressive effect. Free radicals, histamine, eicosanoids and platelet-activating factor have been shown to be involved in dithranol-induced dermatitis, and the oxidation products of the drug are responsible for the staining. Our experimental data suggest that extracellularly generated oxygen free radicals are responsible for both the antipsoriatic and irritative effect of the drug. Furthermore, we could recently provide evidence that extracellularly generated superoxide anion radical also induces an active adaptation mechanism resulting in increased tolerance to dithranol upon repeated application. This adaptive process may explain the requirement for increasing dithranol concentrations to maintain the antipsoriatic efficacy, and also the beneficial effect of other antipsoriatic modalities such as UV-B on dithranol-induced dermatitis. The recognition of this adaptive mechanism may open future prospects to overcome some limitations concerning the practical use of dithranol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2202336     DOI: 10.1159/000210836

Source DB:  PubMed          Journal:  Skin Pharmacol        ISSN: 1011-0283


  10 in total

1.  [Prof. Dr. h.c. mult Otto Braun-Falco and Hungarian dermatology].

Authors:  S Kárpáti; L Kemény
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

2.  Effect of locally applied WEB 2086, a platelet-activating factor antagonist, on inflammatory skin conditions in mice.

Authors:  L Kemény; V Trach; A Dobozy
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

3.  Release of histamine in whole blood by oxygen radicals: division between specific and unspecific processes.

Authors:  B Poch; F Gansauge; S Gansauge; T Anger; U Nilsson; M H Schoenberg; H G Beger
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

4.  Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.

Authors:  H M Ockenfels; G Nussbaum; T Schultewolter; P M Burger; M Goos
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

5.  Repeated treatment with dithranol induces a tolerance reaction in keratinocytes in vitro.

Authors:  B Farkas; B Bonnekoh; G Mahrle
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

6.  Dithranol-induced down-regulation of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] receptors in a human epidermal cell line.

Authors:  L Kemény; E Gross; P Arenberger; T Ruzicka
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

7.  The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal.

Authors:  Khumoekae Richard; Cole Schonhofer; Leila B Giron; Jocelyn Rivera-Ortiz; Silven Read; Toshitha Kannan; Natalie N Kinloch; Aniqa Shahid; Ruth Feilcke; Simone Wappler; Peter Imming; Marianne Harris; Zabrina L Brumme; Mark A Brockman; Karam Mounzer; Andrew V Kossenkov; Mohamed Abdel-Mohsen; Kerstin Andrae-Marobela; Luis J Montaner; Ian Tietjen
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

8.  A Rare Case of a Chemical Burn: Dithranol with Salicylic Acid.

Authors:  Dharshanan Raj Selva Raj; Bismark Adjei; Omar Farooq Al-Nahhas; Lutfi Kamil; Indira Yonjan
Journal:  World J Plast Surg       Date:  2022-03

Review 9.  Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.

Authors:  Salma A Fereig; Ghada M El-Zaafarany; Mona G Arafa; Mona M A Abdel-Mottaleb
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

10.  Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the IL-36 inflammatory loop in psoriasis.

Authors:  Theresa Benezeder; Clemens Painsi; VijayKumar Patra; Saptaswa Dey; Martin Holcmann; Bernhard Lange-Asschenfeldt; Maria Sibilia; Peter Wolf
Journal:  Elife       Date:  2020-06-02       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.